Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 4 (April)

1. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas.
   Br J Surg, 94(4): 466-72. [Abstract] [Full-text]
2. G2/M cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model.
   J Surg Res, 139(1): 106-12. [Abstract] [Full-text]
3. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system.
   Int J Cancer, 120(10): 2157-64. [Abstract] [Full-text]
4. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
   Clin Cancer Res, 13(7): 2216-25. [Abstract] [Full-text]
5. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
   Clin Cancer Res, 13(7): 2151-7. [Abstract] [Full-text]
6. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.
   Eur J Surg Oncol, 33(3): 266-70. [Abstract] [Full-text]
7. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy.
   Int J Cancer, 120(11): 2344-52. [Abstract] [Full-text]
8. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker.
   Clin Chem, 53(4): 629-35. [Abstract] [Full-text]
9. Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
   Int J Cancer, 120(11): 2393-400. [Abstract] [Full-text]
10. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin.
    Cancer Res, 67(7): 3345-55. [Abstract] [Full-text]
11. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells.
    Cancer Res, 67(7): 3286-94. [Abstract] [Full-text]
12. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
    Cancer Res, 67(7): 2938-43. [Abstract] [Full-text]
13. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
    Anticancer Drugs, 18(5): 569-79. [Abstract] [Full-text]
14. Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells.
    Anticancer Drugs, 18(5): 535-41. [Abstract] [Full-text]
15. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases.
    Ann Surg, 245(4): 573-82. [Abstract] [Full-text]
16. Surgery for recurrent pancreatic ductal adenocarcinoma.
    Ann Surg, 245(4): 566-72. [Abstract] [Full-text]
17. Sonic hedgehog signaling pathway in pancreatic cystic neoplasms and ductal adenocarcinoma.
    Pancreas, 34(3): 340-6. [Abstract] [Full-text]
18. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
    Pancreas, 34(3): 335-9. [Abstract] [Full-text]
19. Gene expression profiling in lymph node-positive and lymph node-negative pancreatic cancer.
    Pancreas, 34(3): 325-34. [Abstract] [Full-text]
20. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Pancreas, 34(3): 318-24. [Abstract] [Full-text]
21. Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis.
    Pancreas, 34(3): 310-7. [Abstract] [Full-text]
22. PancPRO: risk assessment for individuals with a family history of pancreatic cancer.
    J Clin Oncol, 25(11): 1417-22. [Abstract] [Full-text]
23. Dietary mutagen exposure and risk of pancreatic cancer.
    Cancer Epidemiol Biomarkers Prev, 16(4): 655-61. [Abstract] [Full-text]
24. S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples.
    Cancer Epidemiol Biomarkers Prev, 16(4): 649-54. [Abstract] [Full-text]
25. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.
    Mol Cancer Res, 5(4): 309-20. [Abstract] [Full-text]
26. Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis.
    Endoscopy, 39(4): 319-24. [Abstract] [Full-text]
27. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
    Cancer Sci, 98(4): 605-11. [Abstract] [Full-text]
28. NRAGE suppresses metastasis of melanoma and pancreatic cancer in vitro and in vivo.
    Cancer Lett, 250(2): 268-75. [Abstract] [Full-text]
29. Medical treatment of pancreatic cancer.
    Expert Rev Anticancer Ther, 7(4): 533-44. [Abstract] [Full-text]
30. Tumor-stroma interactions in pancreatic ductal adenocarcinoma.
    Mol Cancer Ther, 6(4): 1186-97. [Abstract] [Full-text]
31. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
    Am J Surg, 193(5): 610-3; discussion 613. [Abstract] [Full-text]
32. Cytomorphology and B72.3 labeling of benign and malignant ductal epithelium in pancreatic lesions compared to gastrointestinal epithelium.
    Diagn Cytopathol, 35(5): 300-5. [Abstract] [Full-text]
33. Endoscopic ultrasound-guided biopsies of pancreatic masses: comparison between fine needle aspirations and needle core biopsies.
    Diagn Cytopathol, 35(5): 276-82. [Abstract] [Full-text]
34. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines.
    Clin Exp Immunol, 148(1): 127-35. [Abstract] [Full-text]
35. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005.
    Arch Surg, 142(4): 347-54. [Abstract] [Full-text]
36. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract.
    Br J Cancer, 96(8): 1178-82. [Abstract] [Full-text]
37. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.
    Br J Cancer, 96(8): 1183-90. [Abstract] [Full-text]
38. Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice.
    Int J Cancer, 120(12): 2704-9. [Abstract] [Full-text]
39. Clinicopathologic and immunohistochemical correlation in sporadic pancreatic endocrine tumors: possible roles of utrophin and cyclin D1 in malignant progression.
    Hum Pathol, 38(5): 732-40. [Abstract] [Full-text]
40. Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort.
    Int J Cancer, 120(12): 2665-71. [Abstract] [Full-text]
41. Rapidly growing collagenomas in multiple endocrine neoplasia type I.
    J Am Acad Dermatol, 56(5): 877-80. [Abstract] [Full-text]
42. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Cancer Res, 67(8): 3853-61. [Abstract] [Full-text]
43. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.
    Cancer Res, 67(8): 3545-50. [Abstract] [Full-text]
44. Pancreatic tuberculosis with a pancreaticobiliary fistula.
    Dig Dis Sci, 52(5): 1225-8. [Abstract] [Full-text]
45. Mucinous cystadenocarcinoma of the pancreas developing during hormone replacement therapy.
    Dig Dis Sci, 52(5): 1326-8. [Abstract] [Full-text]
46. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions.
    Gut, 56(5): 637-44. [Abstract] [Full-text]
47. Role of BRCA1 and BRCA2 mutations in pancreatic cancer.
    Gut, 56(5): 601-5. [Abstract] [Full-text]
48. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
    Int J Clin Oncol, 12(2): 111-9. [Abstract] [Full-text]
49. Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade.
    Mod Pathol, 20(5): 552-61. [Abstract] [Full-text]
50. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.
    Mod Pathol, 20(5): 570-8. [Abstract] [Full-text]
51. Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas.
    Mod Pathol, 20(5): 509-13. [Abstract] [Full-text]
52. An extremely rare cause of acute abdomen in pregnancy: ruptured pancreatic mucinous cystadenocarcinoma.
    Pancreas, 34(4): 474-6. [Abstract] [Full-text]
53. Mucinous cystadenocarcinoma of the pancreas during pregnancy.
    Pancreas, 34(4): 470-3. [Abstract] [Full-text]
54. The level of carcinoembryonic antigen and the presence of mucin as predictors of cystic pancreatic mucinous neoplasia.
    Pancreas, 34(4): 466-9. [Abstract] [Full-text]
55. Vascular endothelial growth factor-C secreted by pancreatic cancer cell line promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis.
    Pancreas, 34(4): 444-51. [Abstract] [Full-text]
56. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Pancreas, 34(4): 436-43. [Abstract] [Full-text]
57. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties.
    Pancreas, 34(4): 429-35. [Abstract] [Full-text]
58. Photodynamic therapy for pancreatic cancer.
    Pancreas, 34(4): 385-9. [Abstract] [Full-text]
59. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    J Gastroenterol Hepatol, 22(5): 738-48. [Abstract] [Full-text]
60. Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1.
    Biochem Biophys Res Commun, 357(1): 295-301. [Abstract] [Full-text]
61. Role of endoscopic ultrasound in the diagnosis of intraductal papillary mucinous neoplasms: correlation with surgical histopathology.
    Clin Gastroenterol Hepatol, 5(4): 489-95. [Abstract] [Full-text]
62. Virtual Whipple: preoperative surgical planning with volume-rendered MDCT images to identify arterial variants relevant to the Whipple procedure.
    AJR Am J Roentgenol, 188(5): W451-5. [Abstract] [Full-text]
63. Treatment of advanced pancreatic cancer.
    Semin Oncol, 34(2): S25-30. [Abstract] [Full-text]
64. Central pancreatectomy with pancreaticogastrostomy in children.
    J Pediatr Surg, 42(4): 740-6. [Abstract] [Full-text]
65. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm.
    Int J Radiat Oncol Biol Phys, 68(1): 172-7. [Abstract] [Full-text]
66. Determinants of complications in pancreaticoduodenectomy.
    Eur J Surg Oncol, 33(4): 488-92. [Abstract] [Full-text]
67. Effects of intratumoral injection of CCL2 on monocyte-endothelial cell interactions in mouse pancreatic cancer.
    Microcirculation, 14(3): 241-51. [Abstract] [Full-text]
68. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells.
    J Immunother (1997), 30(4): 370-7. [Abstract] [Full-text]
69. Hospital volume and late survival after cancer surgery.
    Ann Surg, 245(5): 777-83. [Abstract] [Full-text]
70. Conventional versus binding pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial.
    Ann Surg, 245(5): 692-8. [Abstract] [Full-text]
71. Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.
    Am J Pathol, 170(5): 1573-84. [Abstract] [Full-text]
72. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
    Oncogene, 26(19): 2759-68. [Abstract] [Full-text]
73. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer.
    Surgery, 141(5): 610-8. [Abstract] [Full-text]
74. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays.
    Nat Methods, 4(5): 437-44. [Abstract] [Full-text]
75. Targeting signal transduction in pancreatic cancer treatment.
    Expert Opin Ther Targets, 11(5): 673-94. [Abstract] [Full-text]
76. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity.
    Gastroenterology, 132(4): 1447-64. [Abstract] [Full-text]
77. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin.
    Int J Cancer, 121(1): 66-75. [Abstract] [Full-text]
78. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion.
    Int J Cancer, 121(1): 21-32. [Abstract] [Full-text]

© 2004-2008 Pancreatic Cancer Research Today. All Rights Reserved.